10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# CD24

Catalog # PVGS1925

## Product Information

| | |
|---|---|
| **Primary Accession** | P25063 |
| **Species** | Human |
| **Sequence** | Ser27-Gly59 |
| **Purity** | > 95% as determined by Bis-Tris PAGE<br>> 95% as determined by HPLC |
| **Endotoxin Level** | Less than 1EU per μg by the LAL method. |
| **Biological Activity** | Measured by its binding ability in a functional ELISA. Immobilized CD24, GST, Human at 0.5 μg/ml (100 μl/well) on the plate can bind Anti-CD24 Antibody, hFc Tag. Test result was comparable to standard batch. |
| **Expression System** | E.coli |
| **Theoretical Molecular Weight** | 31.6 kDa |
| **Formulation** | Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
| **Reconstitution** | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| **Storage & Stability** | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

## Additional Information

| | |
|---|---|
| **Gene ID** | 100133941 |
| **Other Names** | Signal transducer CD24, Small cell lung carcinoma cluster 4 antigen, CD24, CD24, CD24A |
| **Target Background** | CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. |

## Protein Information

| | |
|---|---|
| **Name** | CD24 |
| **Synonyms** | CD24A |
| **Function** | May have a pivotal role in cell differentiation of different cell types. Signaling could be triggered by the binding of a lectin- like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Modulates B-cell activation responses. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells (PubMed:11313396). In association with SIGLEC10 may be involved in the selective suppression of the immune response to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70 and HSP90. Plays a role in the control of autoimmunity (By similarity). |
| **Cellular Location** | Cell membrane; Lipid-anchor, GPI-anchor. |
| **Tissue Location** | B-cells. Expressed in a number of B-cell lines including P32/ISH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells. |